Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition

DL Simmons, RM Botting, T Hla - Pharmacological reviews, 2004 - ASPET
Nonsteroidal anti-inflammatory drugs (NSAIDs) represent one of the most highly utilized
classes of pharmaceutical agents in medicine. All NSAIDs act through inhibiting …

Ibuprofen: pharmacology, efficacy and safety

KD Rainsford - Inflammopharmacology, 2009 - Springer
Objectives This review attempts to bring together information from a large number of recent
studies on the clinical uses, safety and pharmacological properties of ibuprofen. Ibuprofen is …

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis

C Bombardier, L Laine, A Reicin… - … England Journal of …, 2000 - Mass Medical Soc
Background Each year, clinical upper gastrointestinal events occur in 2 to 4 percent of
patients who are taking nonselective nonsteroidal antiinflammatory drugs (NSAIDs). We …

The coxibs, selective inhibitors of cyclooxygenase-2

GA FitzGerald, C Patrono - New England Journal of Medicine, 2001 - Mass Medical Soc
Nonsteroidal antiinflammatory drugs (NSAIDs) are widely used to treat arthritis, menstrual
pain, and headache. Although they are effective, their long-term use is limited by …

Risk of cardiovascular events associated with selective COX-2 inhibitors

D Mukherjee, SE Nissen, EJ Topol - Jama, 2001 - jamanetwork.com
Atherosclerosis is a process with inflammatory features and selective cyclooxygenase 2
(COX-2) inhibitors may potentially have antiatherogenic effects by virtue of inhibiting …

Osteoarthritis—an untreatable disease?

HA Wieland, M Michaelis, BJ Kirschbaum… - Nature reviews Drug …, 2005 - nature.com
Osteoarthritis is a painful and disabling disease that affects millions of patients. Its aetiology
is largely unknown, but is most likely multi-factorial. Osteoarthritis poses a dilemma: it often …

Cyclooxygenase-2: a therapeutic target

ME Turini, RN DuBois - Annual review of medicine, 2002 - annualreviews.org
▪ Abstract Cyclooxygenase (COX), also known as prostaglandin endoperoxide synthase, is
the key enzyme required for the conversion of arachidonic acid to prostaglandins. Two COX …

Risk of cardiovascular events and rofecoxib: cumulative meta-analysis

P Jüni, L Nartey, S Reichenbach, R Sterchi, PA Dieppe… - The lancet, 2004 - thelancet.com
Background The cyclo-oxygenase 2 inhibitor rofecoxib was recently withdrawn because of
cardiovascular adverse effects. An increased risk of myocardial infarction had been …

Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation

JS Ross, KP Hill, DS Egilman, HM Krumholz - Jama, 2008 - jamanetwork.com
Context Authorship in biomedical publication provides recognition and establishes
accountability and responsibility. Recent litigation related to rofecoxib provided a unique …

COX-1 and COX-2 inhibitors

CJ Hawkey - Best Practice & Research Clinical Gastroenterology, 2001 - Elsevier
By inhibiting prostaglandin synthesis, non-steroidal anti-inflammatory drugs (NSAIDs) cause
mucosal damage, ulceration and ulcer complication throughout the gastrointestinal tract …